Brady Kelly 4

What Happened
Brady Kelly, Chief Operating Officer and Executive Vice President of Seres Therapeutics (MCRB), was granted a derivative award covering 18,750 shares on 2026-07-08. The reported acquisition price is $0.00, indicating an option or similar equity award rather than an open-market purchase. No exercise or sale occurred in this filing.

Key Details

• Transaction date: 2026-07-08; Form 4 filed: 2026-07-10 (appears timely).
• Transaction type/code: A (Grant/award or other acquisition of a derivative).
• Amount: 18,750 shares; reported price: $0.00 (derivative award).
• Vesting (footnote): 25% vests on March 2, 2027; remaining 75% vests in 12 equal quarterly installments thereafter.
• Shares owned after transaction: Not specified in the provided filing details.
• No indication of immediate exercise or sale; this is a compensation grant subject to future vesting.

Context
This filing reflects a standard executive equity grant, commonly used for retention and long-term incentive. Because the award vests over time, it does not represent immediate stock ownership or a market purchase/sale signal. Retail investors should view this as compensation-related rather than a direct market investment by the insider.